Xilio Therapeutics (XLO) EBIT (2020 - 2026)
Xilio Therapeutics (XLO) reported EBIT of -$14.1 million for Q1 2026, down 1.88% on a YoY basis from -$14.4 million in Q1 2025, and down 19.23% sequentially from -$11.8 million in Q4 2025.
Xilio Therapeutics (XLO) EBIT (2020 - 2026) Analysis & Trends
Xilio Therapeutics (XLO) has 7 years of EBIT data on file, last reported at -$14.1 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT fell 1.88% year-over-year to -$14.1 million; the trailing twelve-month figure through Mar 2026 stood at -$42.2 million (up 25.82% YoY), and the FY2025 full-year result was -$42.0 million, up 30.7% from the prior year.
- EBIT eased to -$14.1 million in Q1 2026, from -$11.8 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$1.9 million in Q3 2025 to a low of -$24.6 million in Q2 2022.
- A 5-year average of -$16.8 million and a median of -$17.4 million in 2023 frame the typical range for EBIT.
- Across the five-year window, EBIT decreased 28.47% in 2022 and surged 86.93% in 2025, its largest moves.
- Tracing XLO's EBIT over 5 years: stood at -$23.2 million in 2022, then climbed by 21.74% to -$18.1 million in 2023, then increased by 24.83% to -$13.6 million in 2024, then increased by 13.16% to -$11.8 million in 2025, then decreased by 19.23% to -$14.1 million in 2026.
- Business Quant data shows XLO's EBIT at -$14.1 million in Q1 2026, -$11.8 million in Q4 2025, and -$1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Xilio Therapeutics | 145.49 Mn | -4.81 Mn | - | -14.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.11 Mn |
| Dec 31, 2025 | -11.84 Mn |
| Sep 30, 2025 | -1.93 Mn |
| Jun 30, 2025 | -14.37 Mn |
| Mar 31, 2025 | -13.85 Mn |
| Dec 31, 2024 | -13.63 Mn |
| Sep 30, 2024 | -14.76 Mn |
| Jun 30, 2024 | -14.70 Mn |
| Mar 31, 2024 | -17.49 Mn |
| Dec 31, 2023 | -18.13 Mn |
| Sep 30, 2023 | -17.36 Mn |
| Jun 30, 2023 | -20.12 Mn |
| Mar 31, 2023 | -23.53 Mn |
| Dec 31, 2022 | -23.17 Mn |
| Sep 30, 2022 | -20.21 Mn |
| Jun 30, 2022 | -24.55 Mn |
| Mar 31, 2022 | -21.22 Mn |
| Dec 31, 2021 | -19.56 Mn |
| Sep 30, 2021 | -15.96 Mn |
| Jun 30, 2021 | -23.01 Mn |